Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick L Locke

Showing results (191-200 of 195) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 195 results.
Blood Advances|August 14, 2025
New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell LymphomaUri Greenbaum, Hamza Hashmi, Mahmoud Elsawy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2025
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple MyelomaDoris K Hansen, Lauren C Peres, Danai Dima, et al.
Nature Medicine|March 14, 2023
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapyChristoph K Stein-Thoeringer, Neeraj Y Saini, Eli Zamir, et al.
Blood Cancer Journal|November 28, 2025
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experienceAimaz Afrough, Danai Dima, Beatrice Razzo, et al.
Biorxiv : the Preprint Server for Biology|December 19, 2025
Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myelomaFrancesco Maura, Ciara L Freeman, Kylee H Maclachlan, et al.
Pageof 20

Showing results (191-200 of 195) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 195 results.
Blood Advances|August 14, 2025
New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell LymphomaUri Greenbaum, Hamza Hashmi, Mahmoud Elsawy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2025
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple MyelomaDoris K Hansen, Lauren C Peres, Danai Dima, et al.
Nature Medicine|March 14, 2023
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapyChristoph K Stein-Thoeringer, Neeraj Y Saini, Eli Zamir, et al.
Blood Cancer Journal|November 28, 2025
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experienceAimaz Afrough, Danai Dima, Beatrice Razzo, et al.
Biorxiv : the Preprint Server for Biology|December 19, 2025
Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myelomaFrancesco Maura, Ciara L Freeman, Kylee H Maclachlan, et al.
Pageof 20